The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Lung cancer trial updates at ASCO 2021
Benjamin Besse, MD, PhD, Gustave Roussy Cancer Institute, Paris, discusses results from lung cancer trials that are anticipated in 2021. Prof. Besse describes the Phase III CheckMate 816 (NCT02998528) and the Phase III IMpower010 (NCT02486718) trial, which both assess the efficacy of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) and will help elucidate who will benefit from such treatments. The Phase III J-ALEX trial, which investigates alectinib versus crizotinib in ALK-positive NSCLC, is additionally mentioned. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Benjamin Besse, MD, PhD has received sponsored research funds from 4D Pharma, Abbvie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Inivata, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals.
